163 related articles for article (PubMed ID: 26069117)
1. Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.
Lee SH; Seo KA; Lee YM; Lee HK; Kim JH; Shin C; Ghim JR; Shin JG; Kim DH
Yonsei Med J; 2015 Jul; 56(4):961-7. PubMed ID: 26069117
[TBL] [Abstract][Full Text] [Related]
2. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.
Lee HW; Kim DW; Park JH; Kim SD; Lim MS; Phapale PB; Kim EH; Park SK; Yoon YR
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1161-6. PubMed ID: 19723408
[TBL] [Abstract][Full Text] [Related]
4. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.
Yu X; Zeng X; Shi W; Hu Y; Nie W; Chu N; Huang H
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311073
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China.
Zhu H; Guo SC; Liu ZQ; Wang B; Fu L; Chu NH; Lu Y
Int J Tuberc Lung Dis; 2018 Aug; 22(8):931-936. PubMed ID: 29991404
[TBL] [Abstract][Full Text] [Related]
6. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan.
Hung WY; Yu MC; Chiang YC; Chang JH; Chiang CY; Chang CC; Chuang HC; Bai KJ
Int J Tuberc Lung Dis; 2014 May; 18(5):601-6. PubMed ID: 24903799
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
Davies Forsman L; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar JW; Mansjö M; Hoffner S; Xu B; Schön T; Bruchfeld J
BMJ Open; 2018 Oct; 8(9):e023899. PubMed ID: 30287613
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
Zheng X; Jongedijk EM; Hu Y; Kuhlin J; Zheng R; Niward K; Paues J; Xu B; Davies Forsman L; Schön T; Bruchfeld J; Alffenaar JC
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1158():122397. PubMed ID: 33091676
[TBL] [Abstract][Full Text] [Related]
11. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
[TBL] [Abstract][Full Text] [Related]
14. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
15. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy for multidrug-resistant tuberculosis.
Seung KJ; Becerra MC; Atwood SS; Alcántara F; Bonilla CA; Mitnick CD
Clin Microbiol Infect; 2014 May; 20(5):441-6. PubMed ID: 23991934
[TBL] [Abstract][Full Text] [Related]
18. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis.
Lee SJ; Desta KT; Eum SY; Dartois V; Cho SN; Bae DW; Shin SC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1009-1010():138-43. PubMed ID: 26730550
[TBL] [Abstract][Full Text] [Related]
20. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H
Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
